Modality
Radioligand
MOA
FXIai
Target
CD19
Pathway
PD-1/PD-L1
IgAN
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
~Feb 2019
→ ~May 2020
Phase 2
~Aug 2020
→ ~Nov 2021
Phase 3
Feb 2022
→ Oct 2027
Phase 3Current
NCT03191913
1,169 pts·IgAN
2022-02→2027-10·Not yet recruiting
1,169 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-10-011.5y awayPh3 Readout· IgAN
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P3
Not yet…
Catalysts
Ph3 Readout
2027-10-01 · 1.5y away
IgAN
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03191913 | Phase 3 | IgAN | Not yet recr... | 1169 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Semazasiran | BeiGene | Phase 1 | PD-1 |